Erectile Dysfunction Drugs Market Is Expected to Reach Usd 3.4 Billion Globally in 2019

Submitted by: Submitted by

Views: 83

Words: 2292

Pages: 10

Category: Business and Industry

Date Submitted: 09/10/2014 12:13 AM

Report This Essay

Transparency Market Research

Erectile Dysfunction Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 2019

Published Date 21-Oct-2013

98 Page Report

Buy Now

Request Sample

Press Release

Erectile Dysfunction Drugs Market is Expected to Reach USD 3.4 Billion Globally in 2019: Transparency Market Research

Transparency Market Research State Tower, 90, State Street, Suite 700. Albany, NY 12207 United States www.transparencymarketresearch.com sales@transparencymarketresearch.com

Erectile Dysfunction Drugs Market

REPORT DESCRIPTION

Erectile Dysfunction Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 According to a new market report published by Transparency Market Research "Erectile Dysfunction Drugs Market (Viagra, Cialis, Levitra/Staxyn, Stendra/Spedra, Zydena, MUSE, Mvix and Helleva) -Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global erectile dysfunction drugs market was valued at USD 4.3 billion in 2012 and is expected to decline at a CAGR of (4.5%) from 2013 to 2019, to reach an estimated value of USD 3.4 billion in 2019. Browse the full report with complete TOC at http://www.transparencymarketresearch.com/erectiledysfunction-drugs.html Erectile dysfunction is the inability to attain or maintain penile erection in men, sufficient for successful sexual intercourse. Erectile dysfunction is a common medical disorder primarily affecting men older than 40 years of age. In addition, other than the typical causes of erectile dysfunction, such as diabetes and hypertension, a number of common lifestyle related factors are also associated with development of the condition. These include obesity, excessive alcohol consumption, smoking, use of recreational drugs, and poor physical and psychological health. Commonly, oral drugs belonging to the PDE 5 inhibitors class form the mainstay of erectile dysfunction treatment. Other treatment options...